Somatostatin Receptor-PET/CT/MRI of Head and Neck Neuroendocrine Tumors.
Josephine N RiniGraham KeirChristopher CaravellaA GoenkaAna M FranceschiPublished in: AJNR. American journal of neuroradiology (2023)
Somatostatin receptor-PET detected additional lesions and more extensive disease than contrast-enhanced MR imaging alone, while vertex-to-thigh imaging showed a low incidence of metastatic disease. Somatostatin receptor-PET/MRI enabled superior anatomic delineation of tumor burden, while any discrepancies were readily addressed. Somatostatin receptor-PET/MRI has the potential to play an important role in presurgical and radiation therapy planning of head and neck neuroendocrine tumors.
Keyphrases
- neuroendocrine tumors
- contrast enhanced
- pet ct
- computed tomography
- magnetic resonance imaging
- diffusion weighted
- positron emission tomography
- magnetic resonance
- diffusion weighted imaging
- radiation therapy
- small cell lung cancer
- high resolution
- risk factors
- binding protein
- squamous cell carcinoma
- pet imaging
- dual energy
- photodynamic therapy
- radiation induced
- mass spectrometry
- soft tissue